Eam Investors, LLC Adma Biologics, Inc. Transaction History

Eam Investors, LLC

$581 Million
Q3 2024

A detailed history of Eam Investors, LLC transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Eam Investors, LLC holds 272,634 shares of ADMA stock, worth $5.77 Million. This represents 0.94% of its overall portfolio holdings.

Number of Shares

272,634

Previous 374,977 27.29%

Holding current value

$5.77 Million

Previous $4.19 Million 29.99%

% of portfolio

0.94%

Previous 0.75%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$11.21 - $20.03 $1.15 Million - $2.05 Million	-102,343 Reduced 27.29%	272,634 $5.45 Million
Q2 2024 Aug 12, 2024	SELL	$5.98 - $11.18 $1.48 Million - $2.76 Million	-247,109 Reduced 39.72%	374,977 $4.19 Million
Q1 2024 May 13, 2024	BUY	$4.4 - $6.74 $2.74 Million - $4.19 Million	622,086 New	622,086 $4.11 Million
Q3 2023 Nov 13, 2023	BUY	$3.47 - $4.61 $289,064 - $384,031	83,304 Added 9.43%	967,146 $3.46 Million
Q2 2023 Aug 11, 2023	SELL	$3.12 - $4.22 $473,959 - $641,060	-151,910 Reduced 14.67%	883,842 $3.26 Million
Q1 2023 Jul 12, 2023	BUY	$3.01 - $3.87 $2.08 Million - $2.67 Million	691,082 Added 200.51%	1,035,752 $3.43 Million
Q1 2023 May 12, 2023	SELL	$3.01 - $3.87 $4.23 Million - $5.44 Million	-1,404,928 Reduced 80.3%	344,670 $1.14 Million
Q4 2022 Feb 14, 2023	BUY	$2.47 - $3.88 $796,421 - $1.25 Million	322,438 Added 22.59%	1,749,598 $6.79 Million
Q3 2022 Nov 14, 2022	BUY	$2.03 - $2.86 $363,418 - $512,008	179,024 Added 14.34%	1,427,160 $3.47 Million
Q2 2022 Aug 12, 2022	BUY	$1.43 - $2.2 $1.78 Million - $2.75 Million	1,248,136 New	1,248,136 $2.47 Million

Others Institutions Holding ADMA

# of Institutions

319

Shares Held

185M

Call Options Held

917K

Put Options Held

91.6K

View Full List

About ADMA BIOLOGICS, INC.

Ticker ADMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 196,356,992
Market Cap $4.16B
Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...

More about ADMA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eam Investors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eam Investors, LLC with notifications on news.

Account

Eam Investors, LLC Adma Biologics, Inc. Transaction History